Literature DB >> 27841936

Androgen Receptor in the Ovary Theca Cells Plays a Critical Role in Androgen-Induced Reproductive Dysfunction.

Yaping Ma1, Stanley Andrisse1, Yi Chen1, Shameka Childress1, Ping Xue1, Zhiqiang Wang1, Dustin Jones2, CheMyong Ko3, Sara Divall4, Sheng Wu1,2.   

Abstract

Androgen and its receptor (AR) play a critical role in reproductive function under both physiological and pathophysiological conditions. Female AR global knockout mice are subfertile due to both neuroendocrine and ovarian defects. Female offspring from prenatally androgenized heterozygous AR pregnant mice showed rescued estrous cyclicity and fertility. Ar is expressed in granulosa cells, theca interstitial cells, and oocytes in the ovary. We created mice with theca-specific deletion of Ar (ThARKO) by crossing Cyp17-iCre mice that express Cre recombinase under cytochrome P450 17A1 (Cyp17) promoter with Arfl/fl mice. ThARKO mice exhibited no significant differences in pubertal onset or fertility compared with control littermates, and neither estrogen or testosterone levels were different between these groups. Therefore, Ar expression in theca cells likely does not influence fertility nor androgen levels in female mice. We then tested the role of AR in theca cells under hyperandrogenemic condition. After treatment with a pathophysiological level of dihydrotestosterone (DHT), control mice (control-DHT) showed acyclicity and infertility. However, estrous cycles and fertility were altered to a significantly less degree in ThARKO-DHT mice than in control-DHT mice. Messenger RNA (mRNA) levels of Lhcgr (luteinizing hormone receptor) and Timp1 (tissue inhibitor of metalloproteinase 1, and inhibitor of matrix metalloproteinase) were significantly lower in control-DHT ovary compared with control-no DHT ovaries, whereas mRNA levels of Fshr (follicle-stimulating hormone receptor) were significantly higher. Timp1 gene expression was comparable in the ThARKO-DHT and the control-no DHT ovary. We speculate that the preserved level of Timp1 in ThARKO-DHT mice contributes to retained reproductive function.
Copyright © 2017 by the Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27841936      PMCID: PMC5412974          DOI: 10.1210/en.2016-1608

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  54 in total

1.  Sex steroid-mediated regulation of macrophage/monocyte function in a two-hit model of trauma-hemorrhage and sepsis.

Authors:  Thomas Dienstknecht; Martin G Schwacha; Shih Ching Kang; Loring W Rue; Kirby I Bland; Irshad H Chaudry
Journal:  Cytokine       Date:  2004-02-07       Impact factor: 3.861

Review 2.  Steroidogenic versus Metabolic Programming of Reproductive Neuroendocrine, Ovarian and Metabolic Dysfunctions.

Authors:  Rodolfo C Cardoso; Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  Neuroendocrinology       Date:  2015-04-01       Impact factor: 4.914

Review 3.  Molecular control of ovulation and luteinization in the primate follicle.

Authors:  Richard L Stouffer; Fuhua Xu; Diane M Duffy
Journal:  Front Biosci       Date:  2007-01-01

4.  Jak2 is necessary for neuroendocrine control of female reproduction.

Authors:  Sheng Wu; Sara Divall; Gloria E Hoffman; Wei Wei Le; Kay-Uwe Wagner; Andrew Wolfe
Journal:  J Neurosci       Date:  2011-01-05       Impact factor: 6.167

5.  Cloning of human androgen receptor complementary DNA and localization to the X chromosome.

Authors:  D B Lubahn; D R Joseph; P M Sullivan; H F Willard; F S French; E M Wilson
Journal:  Science       Date:  1988-04-15       Impact factor: 47.728

6.  Knockout of luteinizing hormone receptor abolishes the effects of follicle-stimulating hormone on preovulatory maturation and ovulation of mouse graafian follicles.

Authors:  Tomi Pakarainen; Fu-Ping Zhang; Laura Nurmi; Matti Poutanen; Ilpo Huhtaniemi
Journal:  Mol Endocrinol       Date:  2005-06-07

7.  Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome.

Authors:  Jessica K Wickenheisser; Velen L Nelson-DeGrave; Karen L Hendricks; Richard S Legro; Jerome F Strauss; Jan M McAllister
Journal:  J Clin Endocrinol Metab       Date:  2005-05-24       Impact factor: 5.958

Review 8.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Héctor F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  Fertil Steril       Date:  2008-10-23       Impact factor: 7.329

9.  Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.

Authors:  Miriam E Silfen; Michelle R Denburg; Alexandra M Manibo; Rogerio A Lobo; Richard Jaffe; Michel Ferin; Lenore S Levine; Sharon E Oberfield
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

10.  Placental steroidogenesis in pregnant women with polycystic ovary syndrome.

Authors:  Manuel Maliqueo; Hernán E Lara; Fernando Sánchez; Bárbara Echiburú; Nicolás Crisosto; Teresa Sir-Petermann
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2012-11-02       Impact factor: 2.435

View more
  26 in total

Review 1.  The ovarian stroma as a new frontier.

Authors:  Hadrian M Kinnear; Claire E Tomaszewski; Faith L Chang; Molly B Moravek; Min Xu; Vasantha Padmanabhan; Ariella Shikanov
Journal:  Reproduction       Date:  2020-09       Impact factor: 3.906

2.  Female Offspring From Chronic Hyperandrogenemic Dams Exhibit Delayed Puberty and Impaired Ovarian Reserve.

Authors:  Zhiqiang Wang; Mingjie Shen; Ping Xue; Sara A DiVall; James Segars; Sheng Wu
Journal:  Endocrinology       Date:  2018-02-01       Impact factor: 4.736

Review 3.  Impact of Exogenous Testosterone on Reproduction in Transgender Men.

Authors:  Molly B Moravek; Hadrian M Kinnear; Jenny George; Jourdin Batchelor; Ariella Shikanov; Vasantha Padmanabhan; John F Randolph
Journal:  Endocrinology       Date:  2020-03-01       Impact factor: 4.736

Review 4.  Impact of estrogens in males and androgens in females.

Authors:  Stephen R Hammes; Ellis R Levin
Journal:  J Clin Invest       Date:  2019-05-01       Impact factor: 14.808

Review 5.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

6.  Gonadotrope androgen receptor mediates pituitary responsiveness to hormones and androgen-induced subfertility.

Authors:  Zhiqiang Wang; Mingxiao Feng; Olubusayo Awe; Yaping Ma; Mingjie Shen; Ping Xue; Rexford Ahima; Andrew Wolfe; James Segars; Sheng Wu
Journal:  JCI Insight       Date:  2019-08-08

7.  Insulin signaling displayed a differential tissue-specific response to low-dose dihydrotestosterone in female mice.

Authors:  Stanley Andrisse; Katelyn Billings; Ping Xue; Sheng Wu
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-12-19       Impact factor: 4.310

8.  A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome.

Authors:  Ping Xue; Zhiqiang Wang; Xiaomin Fu; Junjiang Wang; Gopika Punchhi; Andrew Wolfe; Sheng Wu
Journal:  J Vis Exp       Date:  2018-10-02       Impact factor: 1.355

9.  A mouse model to investigate the impact of testosterone therapy on reproduction in transgender men.

Authors:  H M Kinnear; E S Constance; A David; E E Marsh; V Padmanabhan; A Shikanov; M B Moravek
Journal:  Hum Reprod       Date:  2019-10-02       Impact factor: 6.918

10.  Developmental Programming: Sheep Granulosa and Theca Cell-Specific Transcriptional Regulation by Prenatal Testosterone.

Authors:  Muraly Puttabyatappa; Xingzi Guo; John Dou; Daniel Dumesic; Kelly M Bakulski; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.